Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
Emerging Infections Program

Twenty Years of Active Bacterial Core Surveillance

Gayle LangleyComments to Author , William Schaffner, Monica M. Farley, Ruth Lynfield, Nancy M. Bennett, Arthur L. Reingold, Ann Thomas, Lee H. Harrison, Megin Nichols, Susan Petit, Lisa Miller, Matthew R. Moore, Stephanie J. Schrag, Fernanda C. Lessa, Tami H. Skoff, Jessica R. MacNeil, Elizabeth Briere, Emily J. Weston, and Chris Van Beneden
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (G. Langley, M.R. Moore, S.J. Schrag, F.C. Lessa, T.H. Skoff, J.R. MacNeil, E.C. Briere, E.J. Weston, C. Van Beneden); Vanderbilt University School of Medicine, Nashville, Tennessee, USA (W. Schaffner); Emory University School of Medicine and The Atlanta VA Medical Center, Atlanta (M.M. Farley); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield); University of Rochester, Rochester, New York, USA (N.M. Bennett); University of California, Berkley, California, USA (A. Reingold); Oregon Department of Human Services, Portland, Oregon, USA (A. Thomas); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (L.H. Harrison); New Mexico Department of Health, Santa Fe, New Mexico, USA (M. Nichols); Connecticut Department of Public Health, Hartford, Connecticut, USA (S. Petit); Colorado Department of Public Health and Environment, Denver, Colorado, USA (L. Miller)

Main Article

Table 2

Questions left unanswered with regard to Active Bacterial Core surveillance*

Organism or disease
Streptococcus pneumoniae
Should PCV13 be recommended for adults?
What proportion of invasive pneumococcal disease is preventable with vaccine?
What other strategies are available to prevent non–vaccine type disease?
Neisseria meningitidis
Should serogroup B vaccines be recommended for routine use in the United States?
Haemophilus influenzae
Are control strategies (e.g., chemoprophylaxis, vaccines) needed for non-Hib disease?
Group B Streptococcus
Will antimicrobial drug resistance reduce the effectiveness of intrapartum prophylaxis?
What will be the projected effect of vaccines on infant disease?
Are there interventions to reduce infant late-onset disease?
Group A Streptococcus
What age groups should be targeted for vaccines according to potential effect on invasive disease?
Can modifiable risk factors for HACO MRSA be identified?
What are effective strategies for preventing infections outside acute-care settings?
Does the acellular vaccine given during pregnancy effectively prevent pertussis in infants?
What is the effect of newly emerging Bordatella pertussis strain changes on disease epidemiology, clinical presentation, and vaccine effectiveness?
Legionellosis Why are rates higher among black than white persons and higher among men than women?
Why do rates differ by geographic area?

*PCV13, 13-valent pneumococcal conjugate vaccine; Hib, H. influenzae type b; HACO, health care–associated community onset; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.